Comparative Pharmacology
Head-to-head clinical analysis: LO MINASTRIN FE versus LO BLISOVI FE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LO MINASTRIN FE versus LO BLISOVI FE.
LO MINASTRIN FE vs LO-BLISOVI FE
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). Inhibits ovulation by suppressing gonadotropin release; increases viscosity of cervical mucus, inhibiting sperm penetration; alters endometrial lining, reducing implantation likelihood.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; norethindrone induces endometrial changes, increasing cervical mucus viscosity.
Prevention of pregnancyTreatment of moderate acne vulgaris in females ≥15 years of age who have no known contraindications, desire oral contraception, and have achieved menarche
Prevention of pregnancyTreatment of heavy menstrual bleeding (off-label)Acne vulgaris (off-label)
1 tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol/ferrous fumarate 75 mg) orally once daily for 28 consecutive days.
One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo tablets.
None Documented
None Documented
Norethindrone: 8-11 hours; ethinyl estradiol: 12-16 hours. Steady-state achieved after 5-7 days of dosing.
Terminal elimination half-life: 15-18 hours for ethinyl estradiol; clinical context: supports once-daily dosing
Hepatic via CYP3A4 (ethinyl estradiol) and primarily reduction and conjugation (norethindrone); undergoes first-pass metabolism.
Hepatic via CYP3A4 (ethinyl estradiol) and primarily conjugation (norethindrone); first-pass metabolism.
Renal: 40-50% as conjugated metabolites; fecal: 20-30% via biliary excretion; unchanged drug <1%.
Renal (approximately 60% as metabolites, 10-15% as unchanged drug); fecal (about 20-30%)
Norethindrone: 97% bound (primarily to albumin and SHBG); ethinyl estradiol: 98% bound (primarily to albumin).
Ethinyl estradiol: 95-98% bound to albumin and sex hormone-binding globulin (SHBG)
Norethindrone: 4 L/kg; ethinyl estradiol: 2-4 L/kg; reflects extensive tissue distribution and binding to sex hormone receptors.
Ethinyl estradiol: 2-5 L/kg; indicates extensive tissue distribution
Oral: norethindrone ~64%, ethinyl estradiol ~40-48% due to first-pass metabolism.
Oral: ethinyl estradiol approximately 40-50% (first-pass metabolism)
No dose adjustment required for mild to moderate renal impairment (GFR ≥30 mL/min). Contraindicated in severe renal impairment (GFR <30 mL/min) or acute renal failure due to potential for hyperkalemia from ferrous fumarate.
No dose adjustment required in renal impairment. Use with caution if severe renal impairment or nephrotic syndrome due to potential fluid retention.
Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). For Child-Pugh class A, use caution; consider lower dose estrogen combination if necessary.
Contraindicated in acute hepatic disease or severe cirrhosis (Child-Pugh class C). Not recommended in moderate impairment (Child-Pugh B) without specialist advice. No data for mild (Child-Pugh A); use caution.
Not indicated for use prepubertal. Approved for females of reproductive potential; safety and efficacy in children <12 years not established. Follow adult dosing postmenarche.
Not indicated in pediatric patients before menarche. For postmenarchal females, same adult dose may be used; weight-based dosing not established.
Not indicated for use in postmenopausal women. In women >35 years who smoke, use is contraindicated due to increased cardiovascular risk.
Not indicated in postmenopausal women. No specific geriatric dose adjustments; consider increased risk of thrombotic events and comorbidities.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (>35 years) and with heavy smoking (≥15 cigarettes/day). Women >35 years who smoke should not use combination oral contraceptives.
Cigarette smoking increases risk of serious cardiovascular events from COC use. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use COCs.
["Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebrovascular accidents, myocardial infarction)","Hepatic disease (benign/malignant tumors)","Hypertension","Gallbladder disease","Carbohydrate/lipid metabolism effects","Ocular changes (retinal thrombosis)","Headache/migraine","Uterine bleeding irregularities","Depression","Cervical cancer screening","Pregnancy test prior to initiation","Lactation (possible decreased milk production)"]
["Thrombotic disorders (DVT, PE, stroke, MI)","Carcinoma (breast, cervical, liver)","Hepatic disease (jaundice, cholestasis)","Hypertension","Carbohydrate/lipid effects","Headache/migraine","Bleeding irregularities","Drug interactions (CYP3A4 inducers/inhibitors)","Depression","Gallbladder disease","Hereditary angioedema"]
["Thrombophlebitis or thromboembolic disorders (current or history)","Cerebrovascular or coronary artery disease","Known or suspected breast carcinoma","Carcinoma of endometrium or other estrogen-dependent neoplasia","Undiagnosed abnormal genital bleeding","Cholestatic jaundice of pregnancy or jaundice with prior pill use","Hepatic adenoma or carcinoma","Known or suspected pregnancy","Hypersensitivity to any component","Heavy smoking (>15 cigarettes/day) in women >35 years"]
["Venous or arterial thrombotic/thromboembolic events (current or history)","Cerebrovascular or coronary artery disease","Valvular heart disease with complications","Uncontrolled hypertension","Major surgery with prolonged immobilization","Diabetes with vascular involvement","Headache with focal neurological symptoms or migraine with aura (age ≥35)","Current or history of breast cancer or other estrogen-sensitive neoplasia","Hepatic adenomas or malignant liver tumors","Acute or chronic liver disease with abnormal function","Undiagnosed abnormal uterine bleeding","Known or suspected pregnancy","Cigarette smoking in women >35 years","Hypersensitivity to any component"]
Data Pending Review
Data Pending Review
No significant food interactions. Grapefruit juice may increase ethinyl estradiol levels, but clinical significance is minimal. Avoid alcohol if liver function is compromised. Iron absorption from ferrous fumarate is enhanced by vitamin C, but not clinically important.
Grapefruit juice may increase estrogen levels and risk of adverse effects; avoid large quantities. Iron absorption is enhanced by vitamin C (e.g., orange juice) and inhibited by tannins (tea, coffee), calcium (dairy), and phytates (whole grains); separate iron intake from these foods by at least 2 hours. Take with food to reduce GI upset.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester use associated with cardiovascular defects, neural tube defects; second/third trimester use associated with fetal genital changes, hepatic adenoma.
Pregnancy category X. Combination hormonal contraceptives are contraindicated in pregnancy due to known risks to the fetus, including cardiovascular and limb defects from first-trimester exposure, and potential feminization of male fetuses from progestin exposure. Post-conception use is not indicated; if exposure occurs, evaluate for pregnancy.
Excreted in breast milk in small amounts (M/P ratio ~0.5). No adverse effects reported in infants, but may reduce milk production. Use with caution.
Small amounts of progestins and estrogens are excreted in breast milk; M/P ratio not established for this specific formulation. Use in breastfeeding women is generally not recommended due to potential effects on milk production and composition, and possible long-term effects on the infant. Alternative contraception methods are advised until weaning.
No dose adjustment indicated as drug is contraindicated in pregnancy.
Contraindicated in pregnancy. If pregnancy occurs, discontinue immediately. No dose adjustment is applicable as the drug should not be used in pregnancy. Pharmacokinetic changes in pregnancy (increased clearance) are irrelevant due to contraindication.
Category C
Category C
LO MINASTRIN FE is a low-dose combination oral contraceptive (1 mg norethindrone acetate / 20 mcg ethinyl estradiol) with ferrous fumarate tablets. It is indicated for contraception and may improve menstrual regularity. The iron component is not bioavailable during active hormone intake; iron tablets are placebo-day supplements. Monitor for thromboembolic risks, especially in smokers over 35. Breakthrough bleeding is common in the first few cycles. Do not use in hepatic disease or known pregnancy.
LO-BLISOVI FE (norethindrone acetate/ethinyl estradiol/ferrous fumarate) is a combined oral contraceptive with iron supplementation. The iron component (75 mg ferrous fumarate) compensates for menstrual blood loss. Administer at the same time daily to maintain stable hormone levels. Missed doses increase risk of breakthrough bleeding and contraceptive failure. Consider non-oral contraceptives in patients with malabsorption or vomiting.
Take one tablet daily at the same time; the last 7 tablets contain iron instead of hormones.Missed dose: if missed within 12 hours, take it as soon as remembered; if more than 12 hours, skip the missed dose and continue schedule; use back-up contraception for 7 days.Smoking increases risk of serious cardiovascular side effects; avoid smoking, especially if over 35 years old.Inform your healthcare provider of any new onset headaches, chest pain, leg pain/swelling, or visual disturbances.Breakthrough bleeding is common initially; if persistent, consult your doctor.Use additional non-hormonal contraception during first 7 days of starting the pill.Store at room temperature; keep out of reach of children; iron tablets may be harmful to children if ingested.
Take one tablet daily at the same time with food to reduce nausea.Missed doses: if one dose is missed >12 hours, take it immediately and continue; if two doses are missed, take two tablets and use backup contraception for 7 days.Iron tablets may cause dark stools; this is harmless.Report severe headache, chest pain, leg swelling, or vision changes immediately.Do not smoke while taking this medication; smoking increases risk of blood clots.Store in original blister pack; do not remove desiccant.